retatrutide triple agonist gip glp-1 glucagon phase 2 obesity A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology Dual and Triple Gut Peptide
Pay in 4 interest-free payments of $6.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
























